Abeona Therapeutics has two late-stage assets nearing FDA decisions and solid market potential despite risks. Read why ABEO ...

Abeona Therapeutics faces a pivotal FDA decision after a CRL-led crash and partial rebound in pz-cel’s valuation. Check out ...

Abeona Therapeutics is positioning itself for a transformative 2025, with pz-cel expected to drive significant growth upon potential FDA approval. The company's strategic focus on market ...

CLEVELAND, April 01, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity ...

Greetings. Welcome to Abeona Therapeutics full year 2024 results and business update conference call. (Operator Instructions) Please note this conference is being recorded. I will now turn the ...

The archived webcast replay will be available for 30 days following the call. Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company developing cell and gene therapies for serious ...

Abeona Therapeutics Inc. announced progress in its Biologics License Application (BLA) review for prademagene zamikeracel (pz-cel), a potential treatment for recessive dystrophic epidermolysis ...

CLEVELAND, March 20, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today reported financial results for the full year of 2024, and announced progress in the ongoing review with ...

CLEVELAND, April 01, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company.

Abeona Therapeutics Inc. (Nasdaq: ABEO) today reported financial results for the full year of 2024, and announced progress in the ongoing review with the U.S. Food and Drug Administration (FDA ...